Please login to the form below

mongersen

This page shows the latest mongersen news and features for those working in and with pharma, biotech and healthcare.

The company’s psoriasis drug Otezla is also underperforming, and another blockbuster candidate mongersen failed in phase III.

Celgene pays $300m upfront for immunology start-up Delinia

other pipeline candidates in this therapeutic category including mongersen for inflammatory bowel disease and ozanimod for multiple sclerosis which are both in late-stage testing.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Add my company

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...